Evaluating disease trajectory during the earliest phases of central nervous system demyelination presents substantial clinical challenges. While magnetic resonance imaging remains the conventional diagnostic benchmark, clinicians frequently encounter subclinical disease progression that standard scans fail to capture. Recent investigations demonstrate that serum neurofilament light chain acts as an indispensable blood biomarker of active axonal injury. By reflecting microscopic neuroaxonal disintegration, this circulating structural protein provides prognostic insights that extend far beyond traditional radiological metrics in clinically isolated syndrome and relapsing-remitting multiple sclerosis.

Clinical Utility of Serum Neurofilament Light Chain in Early Multiple Sclerosis

Neurofilaments constitute major structural cytoskeletal elements within central axons, maintaining caliber and facilitating intracellular transport throughout the nervous system. When inflammatory demyelination or ischemic insult damages axonal membranes, these structural components enter the cerebrospinal fluid and permeate into peripheral circulation. Consequently, quantitative detection of these molecules reflects ongoing neuroaxonal breakdown in real time. Historical diagnostic protocols relied almost exclusively on invasive cerebrospinal fluid sampling through lumbar puncture. Fortunately, advanced ultra-sensitive immunoassay technologies, particularly single-molecule array platforms, now permit accurate quantification from routine venipuncture samples.

Clinicians increasingly appreciate that focal inflammatory lesions visible on neuroimaging do not convey the entire pathological narrative. Diffuse neurodegeneration and chronic compartmentalized inflammation frequently persist in normal-appearing white matter. Therefore, measuring circulating neurofilament levels bridges an essential diagnostic void. It empowers neurologists to identify individuals who experience progressive axonal loss despite exhibiting radiologically quiescent disease on periodic imaging. Consequently, blood-based biomarker monitoring provides a direct biochemical readout of continuous central axonal injury.

Methodological Rigor and Cohort Insights from REFLEX Studies

A rigorous post hoc analysis of the landmark REFLEX and REFLEXION clinical trials evaluated the prognostic capacity of blood biomarkers over five continuous years. The study cohort comprised 262 adult patients presenting with clinically isolated syndrome who initiated early subcutaneous interferon beta-1a therapy. The cohort exhibited a mean age of approximately thirty-two years, a distinct female predominance of sixty-two percent, and a low baseline median Expanded Disability Status Scale score of 1.5.

Researchers calculated age- and body-mass-index-adjusted z-scores to ensure rigorous standardization across the patient collective. Because physiological aging and variable blood volume influence raw concentrations, utilizing standardized z-scores prevents systemic interpretive bias. The investigators tracked biomarker concentrations systematically over the initial two years of therapeutic intervention. They compared these dynamic trajectory patterns against long-term radiological activity and clinical deterioration. Ultimately, this long-term observational framework demonstrated that early biomarker kinetics offer independent predictive value beyond standard clinical trial endpoints and routine diagnostic workups.

Correlations with Magnetic Resonance Imaging Lesion Activity

Baseline data revealed a profound relationship between systemic biomarker levels and acute radiological inflammation. Patients presenting with gadolinium-enhancing lesions demonstrated markedly higher standardized biomarker levels compared to individuals without contrast enhancement. Similarly, subjects harboring high baseline T2 lesion volumes exhibited significantly elevated protein concentrations. These findings confirm that acute focal demyelinating events cause abrupt releases of structural proteins across the compromised blood-brain barrier into peripheral blood.

However, longitudinal follow-up revealed crucial nuances that standard imaging fails to explain. Following the initiation of disease-modifying therapy, systemic biomarker levels declined sharply across the overall cohort, reflecting therapeutic dampening of focal inflammation. Nevertheless, patients who maintained elevated z-scores despite treatment demonstrated persistent subclinical disease activity. Furthermore, persistent elevations predicted the emergence of new or enlarging T2 lesions during subsequent annual scans. Thus, serological surveillance captures focal inflammatory dynamics that remain undetectable between scheduled neuroimaging appointments, providing an invaluable early warning system for therapeutic failure.

Forecasting Accelerated Brain Atrophy and Neurodegeneration

Cerebral volume loss represents one of the most reliable radiological markers of irreversible neurodegeneration in multiple sclerosis. In this longitudinal investigation, higher baseline biomarker z-scores directly correlated with accelerated annualized brain parenchymal volume loss over five years. Moreover, patients exhibiting persistent biomarker elevation over the initial twenty-four months developed significantly greater whole-brain and cortical grey matter atrophy across the extended follow-up period.

Importantly, multivariable regression models demonstrated that this association remained statistically robust even after researchers adjusted for baseline lesion counts and initial brain volume. Conventional imaging scans often display pseudoatrophy or temporary volumetric fluctuations caused by resolved edema and anti-inflammatory drug mechanisms. In contrast, circulating neurofilament levels provide a pure, biological indicator of actual structural demise. As a result, tracking these systemic markers allows physicians to detect subtle, smoldering neurodegenerative processes long before volumetric loss becomes irreversible and readily discernible on annual scans. This capability offers invaluable assistance in clinical trials and daily neuro-rehabilitation planning.

Predicting Long-Term Disability and Guiding Early Treatment Decisions

Preventing irreversible physical impairment remains the primary therapeutic objective in managing multiple sclerosis. The REFLEX and REFLEXION analyses examined confirmed disability progression over five years using the Expanded Disability Status Scale. Patients exhibiting high baseline biomarker scores faced a significantly higher hazard of clinical disability worsening than those with low concentrations. Furthermore, participants who failed to suppress biomarker concentrations during the first two years showed the greatest risk of unremitting neurological decline.

Crucially, standard magnetic resonance imaging parameters only partially accounted for this long-term clinical deterioration. When statisticians incorporated both radiological metrics and biomarker values into predictive models, the biomarker z-scores contributed independent, additive prognostic power. This critical finding underscores that visible demyelinating plaques capture only a fraction of ongoing neurological injury. Therefore, incorporating peripheral biomarker measurements alongside conventional neuroimaging substantially refines individualized prognostic stratification. Neurologists can thus differentiate between patients who maintain stable neurological function and those destined for progressive disability despite minimal visible lesion accumulation, guiding early escalation to high-efficacy therapies.

Frequently Asked Questions

How does serum neurofilament light chain complement MRI in early multiple sclerosis?

Magnetic resonance imaging reliably detects focal inflammatory lesions and macroscopic tissue damage. However, serum neurofilament light chain reflects acute and diffuse axonal degeneration throughout the central nervous system. Consequently, combining fluid biomarkers with neuroimaging provides clinicians with a sensitive, comprehensive assessment of ongoing disease activity and future disability risk.

Why do clinicians use age-adjusted z-scores for neurofilament interpretation?

Serum biomarker concentrations naturally rise as individuals age due to physiological neuronal turnover. Furthermore, variable body mass index affects circulating blood volumes and biomarker concentration. Therefore, clinicians apply age- and weight-adjusted z-scores instead of raw values. This standardized calibration accurately identifies pathological neuroaxonal injury while minimizing false-positive readings in diverse adult cohorts.

Can peripheral biomarker tracking influence therapeutic decision-making in clinically isolated syndrome?

Elevated biomarker concentrations indicate aggressive early neuroaxonal destruction and heightened conversion probability. Therefore, elevated levels alert treating neurologists to initiate high-efficacy disease-modifying therapies rather than moderate platform agents. Moreover, serial monitoring demonstrates therapeutic response when circulating levels normalize, confirming that selected interventions effectively suppress occult underlying central neuroinflammation.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Mattiesing RM et al. The predictive value of serum neurofilament light chain levels beyond MRI measures for clinical and radiological disease progression in the earliest stages of multiple sclerosis. J Neurol. 2026 Sep 09. doi: 10.1007/s00415-026-14100-9. PMID: 42714661.


2. Disanto G, Barro C, Benkert P, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857-870.


3. Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light levels correlate with clinical and radiological disease activity in multiple sclerosis. Lancet Neurol. 2019;18(6):534-544.